Reid Perper

Reid Perper is the Chief Investment Officer of Five Arrows Capital Partners (FACP), the North American corporate private equity strategy within Five Arrows, Rothschild & Co’s alternative assets arm. Rothschild & Co’s profile states that he is also a member of the FACP and FALT Investment Committees.

Before joining Five Arrows in 2017, Perper was a Senior Advisor supporting European investments for Health Evolution Partners, a healthcare-focused private equity firm he joined in 2010. Earlier, he founded Healthcare Investment Partners in 2003 and served as its Managing Director.

Perper’s earlier career was rooted in private equity at Donaldson, Lufkin & Jenrette and Credit Suisse. He began at DLJ in 1988, was a founding member of DLJ Merchant Banking Partners in 1992, and later served as Managing Director of DLJ Merchant Banking Partners and Co-Head of European Private Equity at Credit Suisse.

He holds a BS from Stanford University and an MBA from The Wharton School at the University of Pennsylvania. His board history includes current or prior director roles connected to RLDatix, Kisimul School Holdings, IVAC Holdings, Fiberite Holdings, Charles River Laboratories, Gala Group, Nycomed Holdings, NextPharma Technologies, Biopartners, and Pragma Wealth Management.

• FACP targets lower middle-market companies across North America with enterprise values of $75 million to $500 million.
• The strategy focuses on healthcare, data and software, and technology-enabled business services, especially businesses that can be further enabled by technology.
• FACP’s stated investment criteria include “franchises with dominant market positions,” management teams that care deeply about their companies, high revenue and earnings visibility, and operational levers to unlock latent value.
• Five Arrows describes its broader investment approach around “passion for investing,” “respect for risk,” and a “culture of partnership,” including meaningful alignment among investors, managers, and investment professionals.
• The firm’s corporate private equity platform emphasizes defensible market positions, strong management teams, high visibility of organic unit growth, strong unit economics, and operational value creation.
• This is not a seed-stage angel profile based on verified sources; the public evidence points to institutional private equity and growth/buyout investing.